Trevi Therapeutics Inc (TRVI)

06:55 AM

Trevi Therapeutics Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia

06:55 AM

03:56 AM

What analysts say about Trevi Therapeutics Inc. stockConsistent wealth multiplication - PrintWeekIndia

03:56 AM

09:54 AM

What drives Trevi Therapeutics Inc. stock priceUnprecedented profit potential - PrintWeekIndia

09:54 AM

08:48 AM

Is Trevi Therapeutics Inc. a good long term investmentHigh-profit trading signals - Autocar Professional

08:48 AM

06:54 AM

Will Trevi Therapeutics Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com

06:54 AM

12:20 PM

How Trevi Therapeutics Inc. stock reacts to Fed policy changesRapid growth trajectories - jammulinksnews.com

12:20 PM

Jul 24, 2025

Should I buy Trevi Therapeutics Inc. stock before earningsTurbocharged investment results - jammulinksnews.com

Jul 24, 2025

Jul 23, 2025

The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister

Jul 23, 2025

Jul 23, 2025

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha

Jul 23, 2025

Jul 22, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - Eastern Progress

Jul 22, 2025

Jul 22, 2025

How Trevi Therapeutics Inc. stock performs during market volatilityFree Access to Investors Club - Newser

Jul 22, 2025

Jul 16, 2025

Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - simplywall.st

Jul 16, 2025

Jul 15, 2025

Why Trevi Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025

Jul 15, 2025

What makes Trevi Therapeutics Inc. stock price move sharplyFree Smart Investment Opportunities - Newser

Jul 15, 2025

Jul 13, 2025

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - The Globe and Mail

Jul 13, 2025

Jul 11, 2025

Trevi Therapeutics (TRVI) Price Target Predicts 231.05% Upside Potential - AInvest

Jul 11, 2025

Jul 11, 2025

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - Yahoo Finance

Jul 11, 2025

Jul 09, 2025

31,359 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Vontobel Holding Ltd. - Defense World

Jul 09, 2025

Jul 04, 2025

Cantor Fitzgerald Comments on TRVI FY2025 Earnings - Defense World

Jul 04, 2025

Jul 01, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism | TRVI Stock News - GuruFocus

Jul 01, 2025

Jul 01, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism. - AInvest

Jul 01, 2025

Jun 30, 2025

Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025

Jun 28, 2025

Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart.com

Jun 28, 2025

Jun 26, 2025

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. ... - Bluefield Daily Telegraph

Jun 26, 2025

Jun 17, 2025

Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks

Jun 17, 2025

Jun 14, 2025

Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World

Jun 14, 2025